SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

MAAT (MAAT) News

Follow MAAT (MAAT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol MAAT Asset market Sector Markets 90 days 7 Updated Sep 29, 2026, 04:17 PM UTC Open live news feed
L France's MaaT Pharma H1 operating loss widens on higher R&D costs OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feed NEWS | Sep 29, 2026, 04:17 PM UTC L MaaT Pharma 1H Rev EUR1.1M >MAAT.FR MaaT Pharma 1H Rev EUR1.1M >MAAT.FR NEWS | Sep 29, 2026, 04:07 PM UTC L MaaT Pharma (MAAT) Posts H1 Loss, Extends Cash Runway To December 2026 MaaT Pharma reported H1 2026 revenue of €1.1M (vs €2.4M in H1 2025) and operating loss of €18.3M (vs €15.1M), with cash of €17.1M at June 30 and cash runway now extended to December 2026.Material DetailsContext by AI Ana EARNINGS | Sep 29, 2026, 04:00 PM UTC L MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update Regulatory News:MaaT Pharma (EURONEXT:MAAT — the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients w NEWS | Sep 29, 2026, 04:00 PM UTC M MaaT Pharma schedules FDA Pre-IND for MaaT034 MaaT Pharma says it has scheduled an FDA Pre-IND meeting for MaaT034 in Oct 2026, focused on CMC. The company targets first-in-human study start in late 2027, pending regulatory clearance and funding. EQUITY | Sep 21, 2026, 05:00 PM UTC M CHMP maintains negative opinion on MaaT Pharma’s MaaT013 MaaT Pharma said the CHMP upheld its negative opinion on the CMA for MaaT013 (Xervyteg®) after re-examination. REGULATION | Sep 18, 2026, 05:30 AM UTC L MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe Regulatory News:MaaT Pharma (EURONEXT: MAAT — the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients w NEWS | Sep 15, 2026, 05:30 AM UTC